Vilazodone-Associated Hyperglycemia in a Patient With Diabetes: A Case Report

    loading  Checking for direct PDF access through Ovid


To the Editors
Prospective studies support the assumption of a bidirectional association between depression and non–insulin-dependent diabetes mellitus (type 2 DM).1 Thus, use of antidepressants among depressed patients with diabetes has become inevitable. The noradrenergic, nortriptyline, and selective serotonin reuptake inhibitors (SSRIs) have been reported to worsen glycemic control in people with diabetes.2 Vilazodone is a newer antidepressant with novel mechanism of action whose side effect profile has not been completely known. Vilazodone offers a novel combination of selective serotonin reuptake inhibition and serotonergic (5-HT1A) receptor partial agonist activity; thus, it is termed as serotonin partial agonist-reuptake inhibitor.3 We report a case of moderate depression with well-controlled type 2 DM having hyperglycemia following the initiation of vilazodone.
    loading  Loading Related Articles